We are analyzing https://link.springer.com/article/10.1007/s00280-017-3489-0.

Title:
Positioning of proteasome inhibitors in therapy of solid malignancies | Cancer Chemotherapy and Pharmacology
Description:
Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

pubmed, cancer, article, google, scholar, cas, cells, proteasome, cell, btz, central, pis, apoptosis, bortezomib, activity, solid, resistance, inhibitor, inhibitors, treatment, protein, autophagy, combination, lung, inhibition, pancreatic, therapy, tumor, tumors, effects, drug, clinical, breast, malignancies, cfz, multiple, carcinoma, showed, activation, proteins, myeloma, mechanisms, vitro, lines, efficacy, studies, induction, human, increased, hnscc,

Topics {✒️}

protein/atp-binding cassette b1 article download pdf ire1α-traf2-ask1-jnk pathways dna damage-induced ubiquitylation autologous stem-cell transplantation bortezomib-induced peripheral neuropathy jacqueline cloos declares proteasome inhibitor bortezomi-induced vesicular/exosome-mediated exocytosis small-cell lung cancer fumonsin b1-induced inhibition p-glycoprotein-mediated resistance overcomes mcl-1-mediated resistance apoptosis-related chemotherapy resistance bortezomib/proteasome inhibitor triggers brca1 sensitizes cells thyroid-specific gene expression stimulated btz-induced apoptosis btz-induced cell death endoplasmic-reticulum stress pathway btz versus hmsn-btz pro-apoptotic targets regulated btz-resistant cells featured pro-apoptotic protein noxa reversible boronate-based pi wild-type p53 cells amp-activated protein kinase determine pi sensitivity/resistance atp synthase inhibitor interferon-induced oxidative stress autophagy-mediated lysosomal degradation synergistic anti-tumor activity peptide-based reversing agents induce anti-tumor activity parallel dose-escalation study combined bortezomib-based chemotherapy pi-induced er-stress [48 ubiquitin-proteasome proteolytic pathway showed anti-tumor activity pro-apoptotic protein bim anti-apoptotic protein mcl-1 anti-apoptotic bcl-2 protein integrated safety profile enhanced btz-induced cytotoxicity compared neoplastic b-cells interferon-γ-induced upregulation bortezomib-resistant leukemia cells jacqueline cloos anaplastic thyroid carcinoma reactive oxygen species

Questions {❓}

, Kroon J, Jansen G et al (2013) Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
Green TD, Crews AL, Park J et al (2011) Regulation of mucin secretion and inflammation in asthma: a role for MARCKS protein?
Groettrup M, Kirk CJ, Basler M (2010) Proteasomes in immune cells: more than peptide producers?
San-Miguel JF, Mateos MV (2011) Can multiple myeloma become a curable disease?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Positioning of proteasome inhibitors in therapy of solid malignancies
         description:Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
         datePublished:2017-11-28T00:00:00Z
         dateModified:2017-11-28T00:00:00Z
         pageStart:227
         pageEnd:243
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s00280-017-3489-0
         keywords:
            Proteasome inhibitors
            Bortezomib
            Carfilzomib
            Solid tumors
            Drug resistance
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-017-3489-0/MediaObjects/280_2017_3489_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-017-3489-0/MediaObjects/280_2017_3489_Fig2_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:81
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Margot S. F. Roeten
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jacqueline Cloos
               url:http://orcid.org/0000-0001-9150-8026
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:VU University Medical Center
                     address:
                        name:Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Gerrit Jansen
               affiliation:
                     name:Location VUmc, VU University Medical Center
                     address:
                        name:Amsterdam Rheumatology and Immunology Center, Location VUmc, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Positioning of proteasome inhibitors in therapy of solid malignancies
      description:Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
      datePublished:2017-11-28T00:00:00Z
      dateModified:2017-11-28T00:00:00Z
      pageStart:227
      pageEnd:243
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s00280-017-3489-0
      keywords:
         Proteasome inhibitors
         Bortezomib
         Carfilzomib
         Solid tumors
         Drug resistance
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-017-3489-0/MediaObjects/280_2017_3489_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-017-3489-0/MediaObjects/280_2017_3489_Fig2_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:81
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Margot S. F. Roeten
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jacqueline Cloos
            url:http://orcid.org/0000-0001-9150-8026
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:VU University Medical Center
                  address:
                     name:Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Gerrit Jansen
            affiliation:
                  name:Location VUmc, VU University Medical Center
                  address:
                     name:Amsterdam Rheumatology and Immunology Center, Location VUmc, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:81
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:VU University Medical Center
      address:
         name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:Location VUmc, VU University Medical Center
      address:
         name:Amsterdam Rheumatology and Immunology Center, Location VUmc, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Margot S. F. Roeten
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Jacqueline Cloos
      url:http://orcid.org/0000-0001-9150-8026
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
            name:VU University Medical Center
            address:
               name:Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Gerrit Jansen
      affiliation:
            name:Location VUmc, VU University Medical Center
            address:
               name:Amsterdam Rheumatology and Immunology Center, Location VUmc, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
      name:Amsterdam Rheumatology and Immunology Center, Location VUmc, VU University Medical Center, Amsterdam, The Netherlands

External Links {🔗}(732)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Particles.js
Prism.js

CDN Services {📦}

Crossref

5.02s.

LINK . SPRINGER . COM {}